Regina Graul, an officer and director of Korsana Biosciences, Inc., filed a Form 144 notice of proposed sale of securities on November 20, 2026, disclosing her intent to sell common stock through Morgan Stanley Smith Barney LLC.

Key Highlights

  • Seller and roles: Regina Graul is identified in the filing as both an officer and a director of Korsana Biosciences, Inc.
  • Shares proposed for sale: 10,001 shares of common stock, with an aggregate market value of $374,315.43, according to the filing.
  • Shares outstanding: The filing reports 45,541,358 shares of common stock outstanding.
  • Approximate sale date: The filing lists November 20, 2026 as the approximate date of sale, to be executed on NASDAQ.
  • Original acquisition: The securities were acquired as restricted stock from the issuer, with the filing noting an acquisition date of November 7, 2019.
  • No sales in prior three months: The filing reports nothing to disclose under the securities sold during the past three months section.

Proposed Sale Details and Acquisition History for Korsana Biosciences Common Stock

According to the Form 144 filing, Regina Graul, who serves as both an officer and a director of Korsana Biosciences, Inc. (NASDAQ:KRSA), intends to sell 10,001 shares of the company's common stock. The proposed transaction is to be conducted through Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, 8th Floor, New York, NY 10004. The filing lists the aggregate market value of the shares at $374,315.43 and identifies NASDAQ as the exchange on which the sale is to occur.

The filing discloses that the shares to be sold were originally acquired as restricted stock from the issuer. The acquisition date listed is November 7, 2019, and payment is described as "Not Applicable." A remark in the filing states that "the securities to be sold were acquired upon the vesting of restricted stock during the period of 11/07/2019 through 07/16/2026," indicating the shares vested in tranches over a multi-year period. Korsana Biosciences is a biosciences company incorporated and addressed in Waltham, Massachusetts, with SEC file number 001-38787.

The filing further reports that there were no sales of Korsana Biosciences securities by Graul during the three months preceding this notice. By signing the Form 144, Graul represented, as stated in the filing, that she "does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed."

What Was Disclosed

Korsana Biosciences officer and director Regina Graul filed a Form 144 on November 20, 2026, proposing to sell 10,001 shares of common stock with an aggregate market value of $374,315.43, originally acquired as restricted stock beginning November 7, 2019.